Epetraborole in Patients With Mycobacterium Abscessus Lung Disease

计划入组 84 人 · 首次发布于 2025 年 12 月 24 日

The Role of Inflammasome in Inflammatory Macrophage in Mycobacterium Avium Complex-lung Disease and Mycobacterium Abscessus-lung Disease

计划入组 100 人 · 首次发布于 2013 年 12 月 9 日

Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease

计划入组 30 人 · 首次发布于 2017 年 1 月 31 日

Lung Disease Therapy (Metis Pharmaceuticals)

lung inflammatory disease therapy (COPD)

OAT-1441

BATEMAN, TIMOTHY M. M. MD

United States

Lung Therapeutics, Inc.

United States

Sec Lung, LLC

United States

AN2 Therapeutics Advances Three Phase 2 Programs as Boron Chemistry Pipeline Expands

AN2 Therapeutics Receives FDA Clearance for Epetraborole Trial in Mycobacterium abscessus Lung Disease

AN2 Therapeutics Expands Epetraborole Development into Phase 2 Trial for Polycythemia Vera